Description: Almatica Pharma, Inc. has a growing portfolio of mature prescription and OTC pharmaceutical products including Macrobid® and Macrodantin® for frequent UTIs.
urology (292) antibiotics (98) women’s health (63) bacterial infections (29) cystitis (26) urinary tract infections (13) utis (3) almatica (1) alvogen (1) nitrofurantoin (1)
Almatica Pharma, Inc. a subsidiary of Alvogen , is focused on the acquisition of brand Rx products. Established in 2008, Almatica Pharma has a current portfolio that includes pain, anti-infective and cardiovascular treatments.
The parent company of Almatica Pharma, Alvogen, is the next generation pharmaceuticals company. Our business model ensures competitive advantage through focused in-house capabilities and a network of partners for enhanced speed and flexibility. Alvogen currently has commercial operations in 34 countries around the globe, with regional hubs based in North America, Romania and Taiwan.
Our passionate team is committed to continue to grow our business around the world and to becoming a top 10 global generic pharmaceuticals player. North America is our largest market with over 60 pending ANDA filings. Other markets include Romania, Hungary, Korea, Taiwan, Bulgaria and China.